Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report report published on Thursday,Benzinga reports. HC Wainwright currently has a $16.00 price target on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. JMP Securities reissued a “market outperform” rating and issued a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. Cantor Fitzgerald started coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price objective on the stock. The Goldman Sachs Group started coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research report on Friday, December 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $6.75.

Esperion Therapeutics Price Performance

NASDAQ ESPR opened at $1.69 on Thursday. The stock has a market capitalization of $334.36 million, a PE ratio of -2.64 and a beta of 1.04. Esperion Therapeutics has a 1 year low of $1.47 and a 1 year high of $3.94. The business’s 50-day moving average is $1.84 and its 200 day moving average is $2.07.

Institutional Trading of Esperion Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Wasatch Advisors LP grew its stake in shares of Esperion Therapeutics by 4.9% in the 4th quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company’s stock worth $53,861,000 after buying an additional 1,136,245 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Esperion Therapeutics by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after buying an additional 171,609 shares during the last quarter. State Street Corp grew its stake in shares of Esperion Therapeutics by 2.7% in the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after buying an additional 99,802 shares during the last quarter. Two Sigma Advisers LP grew its stake in shares of Esperion Therapeutics by 0.4% in the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock worth $7,956,000 after buying an additional 16,100 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its stake in shares of Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock worth $6,862,000 after buying an additional 1,020,243 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.